Core Viewpoint - Gushengtang Singapore is set to acquire 100% equity and related interests of DA ZHONG TANG PTE. LTD., which will become a subsidiary of the company, enhancing its market presence in Singapore and creating synergies with existing healthcare platforms [1][2] Group 1 - The acquisition agreement was established on November 16, 2025, and will integrate DA ZHONG TANG's financial performance into Gushengtang's consolidated financial statements [1] - The acquisition aligns with the company's strategy to expand its offline medical institution network and increase market share in Singapore [1] - The financial terms of the acquisition were determined through fair negotiations, considering DA ZHONG TANG's historical performance, qualifications, resources, and prospects [2] Group 2 - The acquisition cost will be funded through net proceeds from a placement, idle funds of the group, and Gushengtang Singapore's own capital [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 收購大中堂的股權 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2025年11月16日，本公司附 屬公司Gushengtang Singapore TCM Healthcare Technologies Holdings Private Limited （「Gushengtang Singapore」）與DA ZHONG TANG PTE. LTD.（「大中堂」）的 股 東 （「賣方」）訂立股權轉讓合同（「股權轉讓合同」），據此，Gushengtang Singapore同 意收購，而賣方同意出售大中堂100%股權及相關權益（「收購事項」）。 於收購事項完成後，大中堂將成為本公司的附屬公司，而大中堂的財務業績將 併入本集團的綜合財務報表。本公司將根據香港聯合交易所有限公司證券上 市規則（「上市規則」）於必要時另行作出公告，以提供有關收購事項的最新進展。 – 1 – 有關大中堂的資料 GUSHENGT ...